Martin Kimmich

1.5k total citations
22 papers, 295 citations indexed

About

Martin Kimmich is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Martin Kimmich has authored 22 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Martin Kimmich's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Martin Kimmich is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Martin Kimmich collaborates with scholars based in Germany, Switzerland and United States. Martin Kimmich's co-authors include Godehard Friedel, Martin Kohlhäufl, German Ott, Martin Kohlhäeufl, Martin Schüler, S. Eschmann, Juergen Dippon, Thomas Hehr, Hermann Aebert and Wilfried Budach and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Martin Kimmich

22 papers receiving 292 citations

Peers

Countries citing papers authored by Martin Kimmich

Since Specialization

Citations

This map shows the geographic impact of Martin Kimmich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Kimmich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Kimmich more than expected).

Fields of papers citing papers by Martin Kimmich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Kimmich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Kimmich. The network helps show where Martin Kimmich may publish in the future.

Co-authorship network of co-authors of Martin Kimmich

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Kimmich. A scholar is included among the top collaborators of Martin Kimmich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Kimmich. Martin Kimmich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study. 2023 ·Journal of Clinical Oncology ·Kersti Oselin, Byoung Yong Shim, Morihito Okada, Maciej Bryl, Laura Bonanno, Güzin Demirağ, Ida Colantonio, Martin Kimmich, (unknown), Johan Vansteenkiste, Reyes Bernabé, (unknown), Alessandra Curioni‐Fontecedro, Martin Früh, Mira Wollner, Jing Yang, (unknown), Sandrine Marréaud, Solange Peters, Mary O’Brien	10
2	A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients 2019 ·Journal of Thoracic Oncology ·Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, (unknown), Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te‐Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, (unknown), Volker Wacheck, Gee‐Chen Chang	60
3	Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer 2019 ·Oncology Research and Treatment ·(unknown), Nadežda Basara, Wolfgang Schütte, E. Späth‐Schwalbe, Jürgen Alt, Steffen Thiel, Martin Kimmich, Jürgen R. Fischer, (unknown), Frank Griesinger, Daniel C. Christoph	7
4	Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer 2018 ·Journal of Cancer Research and Clinical Oncology ·Jan Stratmann, Sebastian Michels, (unknown), Daniel C. Christoph, (unknown), Werner Spengler, Helge Bischoff, (unknown), Jürgen Alt, Annette Müller, Eckart Laack, Martin Kimmich, Frank Griesinger, Martin Sebastian	8
5	Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib 2018 ·Pneumologie ·Frank Griesinger, (unknown), (unknown), Barbara Deschler-Baier, Martin Kimmich, Martin Sebastian, Christian Schulz, Wolfram Brugger, Rainer Wiewrodt, Robert Pirker, Martin Früh, Oliver Gautschi, J. Wolf	1
6	Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial 2017 ·Annals of Oncology ·Maja Guberina, Wilfried Eberhardt, Martin Stuschke, Thomas Gauler, Frank Heinzelmann, Danjouma Cheufou, Martin Kimmich, Godehard Friedel, Heinz Schmidberger, Kaid Darwiche, Verena Jendrossek, Martin Schüler, Georgios Stamatis, Christoph Pöttgen	38
7	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial 2017 ·Clinical Lung Cancer ·Suresh S. Ramalingam, M. Pérol, Martin Reck, Rubén Dario Kowalyszyn, Oliver Gautschi, Martin Kimmich, Eun Kyung Cho, Grzegorz Czyżewicz, Alexandru Grigorescu, Nina Karaseva, Shaker R. Dakhil, Pablo Lee, (unknown), Andreas Sashegyi, Ekaterine Alexandris, Gebra Cuyún Carter, Katherine B. Winfree, Edward B. Garon	6
8	A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line treatment for EGFRmt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib. 2017 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, (unknown), Martin Kimmich, Nicolas Girard, Chun‐Ming Tsai, Te‐Chun Hsia, (unknown), Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaron M. Gruver, Johan Wallin, (unknown), Volker Wacheck, Gee‐Chen Chang	6
9	Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced Non-Small Cell Lung Cancer (NSCLC) patient 2016 ·Pneumologie ·Joachim von Pawel, Stefanie Kraff, (unknown), Wilfried Eberhardt, Thomas Gauler, Lothar Müller, Niels Reinmuth, Martin Reck, Martin Kimmich, F. Mayer, H-G. Kopp, (unknown), (unknown), M. Frueh, (unknown), Max Roessler, Berta Moritz, Ulrich Jaehde, Markus Joerger	4
10	ROS1 gene rearrangement and expression of splice isoforms in lung cancer, diagnosed by a novel quantitative RT-PCR assay 2016 ·SHILAP Revista de lepidopterología ·Claudia Kalla, (unknown), Andreas Rosenwald, Martin Kimmich, Martin Kohlhäufl, Godehard Friedel, (unknown)	5
11	Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient. 2015 ·Journal of Clinical Oncology ·Markus Joerger, Joachim von Pawel, Stefanie Kraff, (unknown), Wilfried Eberhardt, Thomas Gauler, Lothar Mueller, Niels Reinmuth, Martin Reck, Martin Kimmich, Frank Mayer, Hans‐Georg Kopp, Dirk Behringer, Yon‐Dschun Ko, M. Frueh, Ralf A. Hilger, Max Roessler, Berta Moritz, Ulrich Jaehde	3
12	Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib 2014 ·The Oncologist ·Martin Schüler, Jürgen R. Fischer, Christian Grohé, S Gütz, Michael Thomas, Martin Kimmich, Claus-Peter Schneider, Eckart Laack, Angela Märten	18
13	Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE). 2014 ·Journal of Clinical Oncology ·Wilfried Eberhardt, Thomas Gauler, Christoph Pöttgen, Godehard Friedel, Stefanie Veit, Vanessa Heinrich, Stefan Welter, Werner Spengler, Martin Kimmich, B. Fischer, Heinz Schmidberger, Eleni Gkika, Sebastian Cordes, Rodrigo Hepp, (unknown), Nils Lehmann, Martin Schüler, Karl‐Heinz Jöckel, Georgios Stamatis, Martin Stuschke	4
14	Pulmonary Adenocarcinoma Occurring 5 Years after Resection of a Primary Pancreatic Adenocarcinoma: A Relevant Differential Diagnosis 2014 ·Case Reports in Oncological Medicine ·(unknown), M Wohlleber, Martin Kimmich, (unknown), Godehard Friedel, German Ott, Martin Kohlhäufl	5
15	Primary Pulmonary Synovial Sarcoma: A Rare Primary Pulmonary Tumor 2013 ·Lung ·(unknown), Martin Kimmich, Andreas Grabner, Heike Horn, Godehard Friedel, German Ott, Martin Kohlhäufl	22
16	Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation 2013 ·SHILAP Revista de lepidopterología ·(unknown), Martin Kimmich, (unknown), Godehard Friedel, German Ott, Martin Kohlhäufl	10
17	Lung Metastasis of Primary Alveolar Soft-Part Sarcoma Occurring 20 Years after Initial Treatment 2013 ·SHILAP Revista de lepidopterología ·(unknown), Martin Kimmich, M Wohlleber, Andreas Grabner, Godehard Friedel, German Ott, Ivo Leuschner, Martin Kohlhäufl	10
18	Late lung metastasis of primary endometrial cancer 2012 ·memo - Magazine of European Medical Oncology ·(unknown), M Wohlleber, Martin Kimmich, (unknown), German Ott, Martin Kohlhäufl	2
19	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: 7-year follow-up of a rare clinicopathologic syndrome 2011 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Martin Kimmich, Godehard Friedel, Andrea Tannapfel, V. Neumann, Martin Kohlhäeufl	15
20	Erfahrungen mit dem eco-Y-Stent® bei 37 Patienten mit tracheobronchialen Stenosen oder ösophago-respiratorischen Fisteln 2009 ·Atemwegs- und Lungenkrankheiten ·(unknown), Godehard Friedel, (unknown), (unknown), Martin Kimmich, Martin Kohlhäufl	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact